| 0 (0%) | 02-21 18:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 34.4 | 1-year : | 40.19 |
| Resists | First : | 29.45 | Second : | 34.4 |
| Pivot price | 28.34 |
|||
| Supports | First : | 26.96 | Second : | 25.42 |
| MAs | MA(5) : | 28.53 |
MA(20) : | 27.8 |
| MA(100) : | 26.38 |
MA(250) : | 26.06  |
|
| MACD | MACD : | 0.4 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 75.1 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 32.68 | Low : | 20.38 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ AMPH ] has closed below upper band by 42.4%. Bollinger Bands are 28.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 29.01 - 29.19 | 29.19 - 29.32 |
| Low: | 27.6 - 27.83 | 27.83 - 27.99 |
| Close: | 28.23 - 28.56 | 28.56 - 28.8 |
Tue, 17 Feb 2026
Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis: Navigating a 10.78% Upside Potential - DirectorsTalk Interviews
Tue, 17 Feb 2026
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Mon, 16 Feb 2026
Denali Advisors LLC Buys New Stake in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Fri, 13 Feb 2026
Amphastar Pharmaceuticals, Novavax, and Organon Shares Skyrocket, What You Need To Know - Finviz
Fri, 13 Feb 2026
Assessing Amphastar Pharmaceuticals (AMPH) Valuation After Mixed Recent Share Performance - Yahoo Finance
Wed, 11 Feb 2026
How (AMPH) Movements Inform Risk Allocation Models - Stock Traders Daily
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 46 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 24.2 (%) |
| Held by Institutions | 73.8 (%) |
| Shares Short | 3,800 (K) |
| Shares Short P.Month | 3,980 (K) |
| EPS | 2.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 16.76 |
| Profit Margin | 15.4 % |
| Operating Margin | 25.2 % |
| Return on Assets (ttm) | 6.7 % |
| Return on Equity (ttm) | 14.8 % |
| Qtrly Rev. Growth | 0.3 % |
| Gross Profit (p.s.) | 7.77 |
| Sales Per Share | 15.74 |
| EBITDA (p.s.) | 4.97 |
| Qtrly Earnings Growth | -52.6 % |
| Operating Cash Flow | 152 (M) |
| Levered Free Cash Flow | 112 (M) |
| PE Ratio | 12.62 |
| PEG Ratio | 0 |
| Price to Book value | 1.7 |
| Price to Sales | 1.81 |
| Price to Cash Flow | 8.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|